|
1
|
Mittnacht S: The retinoblastoma
protein-from bench to bedside. Eur J Cell Biol. 84:97–107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guarducci C, Bonechi M, Boccalini G,
Benelli M, Risi E, Di Leo A, Malorni L and Migliaccio I: Mechanisms
of resistance to CDK4/6 inhibitors in breast cancer and potential
biomarkers of response. Breast Care (Basel). 12:304–308. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hamilton E and Infante JR: Targeting
CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCartney A, Migliaccio I, Bonechi M,
Biagioni C, Romagnoli D, De Luca F, Galardi F, Risi E, De Santo I,
Benelli M, et al: Mechanisms of resistance to CDK4/6 inhibitors:
Potential implications and biomarkers for clinical practice. Front
Oncol. 9:6662019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franco J, Balaji U, Freinkman E,
Witkiewicz AK and Knudsen ES: Metabolic reprogramming of pancreatic
cancer mediated by CDK4/6 inhibition elicits unique
vulnerabilities. Cell Rep. 14:979–990. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Xu K, Liu P, Geng Y, Wang B, Gan
W, Guo J, Wu F, Chin YR, Berrios C, et al: Inhibition of Rb
phosphorylation leads to mTORC2-mediated activation of Akt. Mol
Cell. 62:929–942. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jansen VM, Bhola NE, Bauer JA, Formisano
L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV,
Sánchez V, et al: Kinome-wide RNA interference screen reveals a
role for PDK1 in acquired resistance to CDK4/6 inhibition in
ER-positive breast cancer. Cancer Res. 77:2488–2499. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Litchfield LM, Boehnke K, Brahmachary M,
Mur C, Bi C, Stephens JR, Sauder JM, Gutiérrez SM, McNulty AM, Ye
XS, et al: Combined inhibition of PIM and CDK4/6 suppresses both
mTOR signaling and Rb phosphorylation and potentiates PI3K
inhibition in cancer cells. Oncotarget. 11:1478–1492. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herrera-Abreu MT, Palafox M, Asghar U,
Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M,
Rodriguez O, Grueso J, et al: Early adaptation and acquired
resistance to CDK4/6 inhibition in estrogen receptor-positive
breast cancer. Cancer Res. 76:2301–2313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Franco J, Witkiewicz AK and Knudsen ES:
CDK4/6 inhibitors have potent activity in combination with pathway
selective therapeutic agents in models of pancreatic cancer.
Oncotarget. 5:6512–6525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vora SR, Juric D, Kim N, Mino-Kenudson M,
Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, et al: CDK
4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K
inhibitors. Cancer Cell. 26:136–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
LoRusso PM: Inhibition of the
PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 34:3803–3815.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu W, Yang Z and Lu N: A new role for the
PI3K/Akt signaling pathway in the epithelial-mesenchymal
transition. Cell Adh Migr. 9:317–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berwick DC, Hers I, Heesom KJ, Moule SK
and Tavare JM: The identification of ATP-citrate lyase as a protein
kinase B (Akt) substrate in primary adipocytes. J Biol Chem.
277:33895–33900. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Granchi C: ATP citrate lyase (ACLY)
inhibitors: An anti-cancer strategy at the crossroads of glucose
and lipid metabolism. Eur J Med Chem. 157:1276–1291. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hatzivassiliou G, Zhao F, Bauer DE,
Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA and
Thompson CB: ATP citrate lyase inhibition can suppress tumor cell
growth. Cancer Cell. 8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Migita T, Okabe S, Ikeda K, Igarashi S,
Sugawara S, Tomida A, Taguchi R, Soga T and Seimiya H: Inhibition
of ATP citrate lyase induces an anticancer effect via reactive
oxygen species: AMPK as a predictive biomarker for therapeutic
impact. Am J Pathol. 182:1800–1810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng WW and Kurokawa M: Lipid metabolic
reprogramming as an emerging mechanism of resistance to kinase
inhibitors in breast cancer. Cancer Drug Resist. 3:1–17.
2020.PubMed/NCBI
|
|
21
|
Ray KK, Bays HE, Catapano AL, Lalwani ND,
Bloedon LT, Sterling LR, Robinson PL and Ballantyne CM; CLEAR
Harmony Trial, : Safety and efficacy of bempedoic acid to reduce
LDL cholesterol. N Engl J Med. 380:1022–1032. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Debnath J, Muthuswamy SK and Brugge JS:
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini
grown in three-dimensional basement membrane cultures. Methods.
30:256–268. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egger JV, Lane MV, Antonucci LA, Dedi B
and Krucher NA: Dephosphorylation of the retinoblastoma protein
(Rb) inhibits cancer cell EMT via Zeb. Cancer Biol Ther.
17:1197–1205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Breslin S and O'Driscoll L: The relevance
of using 3D cell cultures, in addition to 2D monolayer cultures,
when evaluating breast cancer drug sensitivity and resistance.
Oncotarget. 7:45745–45756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo X, Cheng C, Tan Z, Li N, Tang M, Yang
L and Cao Y: Emerging roles of lipid metabolism in cancer
metastasis. Mol Cancer. 16:762017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang J, Antin P, Berx G, Blanpain C,
Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori
G, et al: Guidelines and definitions for research on
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol.
21:341–352. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roskoski R Jr: Properties of FDA-approved
small molecule protein kinase inhibitors: A 2022 update. Pharmacol
Res. 175:1060372022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lovly CM and Shaw AT: Molecular pathways:
Resistance to kinase inhibitors and implications for therapeutic
strategies. Clin Cancer Res. 20:2249–2256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoxhaj G and Manning BD: The PI3K-AKT
network at the interface of oncogenic signalling and cancer
metabolism. Nat Rev Cancer. 20:74–88. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
DeBerardinis RJ and Chandel NS:
Fundamentals of cancer metabolism. Sci Adv. 2:e16002002016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kohn AD, Summers SA, Birnbaum MJ and Roth
RA: Expression of a constitutively active Akt Ser/Thr kinase in
3T3-L1 adipocytes stimulates glucose uptake and glucose transporter
4 translocation. J Biol Chem. 271:31372–31378. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roberts DJ, Tan-Sah VP, Smith JM and
Miyamoto S: Akt phosphorylates HK-II at Thr-473 and increases
mitochondrial HK-II association to protect cardiomyocytes. J Biol
Chem. 288:23798–23806. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Currie E, Schulze A, Zechner R, Walther TC
and Farese RV Jr: Cellular fatty acid metabolism and cancer. Cell
Metab. 18:153–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Santos CR and Schulze A: Lipid metabolism
in cancer. FEBS J. 279:2610–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rysman E, Brusselmans K, Scheys K,
Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D,
Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer
cells from free radicals and chemotherapeutics by promoting
membrane lipid saturation. Cancer Res. 70:8117–8126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Srere PA: The citrate cleavage enzyme. I.
Distribution and purification. J Biol Chem. 234:2544–2547. 1959.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bauer DE, Hatzivassiliou G, Zhao F,
Andreadis C and Thompson CB: ATP citrate lyase is an important
component of cell growth and transformation. Oncogene.
24:6314–6322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Szutowicz A, Kwiatkowski J and Angielski
S: Lipogenetic and glycolytic enzyme activities in carcinoma and
nonmalignant diseases of the human breast. Br J Cancer. 39:681–687.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu
H, Li J, Zhu J, Shen Z, Haffty BG, et al: Cullin3-KLHL25 ubiquitin
ligase targets ACLY for degradation to inhibit lipid synthesis and
tumor progression. Genes Dev. 30:1956–1970. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lorito N, Bacci M, Smiriglia A, Mannelli
M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M,
et al: Glucose metabolic reprogramming of ER breast cancer in
acquired resistance to the CDK4/6 inhibitor palbociclib. Cells.
9:6682020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Santarsiero A, Convertini P, Todisco S,
Pierri CL, De Grassi A, Williams NC, Iacobazzi D, De Stefano G,
O'Neill LAJ and Infantino V: ACLY nuclear translocation in human
macrophages drives proinflammatory gene expression by NF-κB
acetylation. Cells. 10:29622021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shi L and Tu BP: Acetyl-CoA and the
regulation of metabolism: Mechanisms and consequences. Curr Opin
Cell Biol. 33:125–131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gnant M, Dueck AC, Frantal S, Martin M,
Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, et al:
Adjuvant palbociclib for early breast cancer: The PALLAS trial
results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 40:282–293.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu F and Korc M: Cdk4/6 inhibition
induces epithelial-mesenchymal transition and enhances invasiveness
in pancreatic cancer cells. Mol Cancer Ther. 11:2138–2148. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rencuzogulları O, Yerlikaya PO, Gürkan AÇ,
Arısan ED and Telci D: Palbociclib, a selective CDK4/6 inhibitor,
restricts cell survival and epithelial-mesenchymal transition in
Panc-1 and MiaPaCa-2 pancreatic cancer cells. J Cell Biochem.
121:508–523. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Z, Li J, Ou Y, Yang G, Deng K, Wang
Q, Wang Z, Wang W, Zhang Q, Wang H, et al: CDK4/6 inhibition blocks
cancer metastasis through a USP51-ZEB1-dependent deubiquitination
mechanism. Signal Transduct Target Ther. 5:252020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Witta SE, Gemmill RM, Hirsch FR, Coldren
CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita
M, et al: Restoring E-cadherin expression increases sensitivity to
epidermal growth factor receptor inhibitors in lung cancer cell
lines. Cancer Res. 66:944–950. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:9652016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Monaco ME: Fatty acid metabolism in breast
cancer subtypes. Oncotarget. 8:29487–29500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hansel DE, Rahman A, House M, Ashfaq R,
Berg K, Yeo CJ and Maitra A: Met proto-oncogene and insulin-like
growth factor binding protein 3 overexpression correlates with
metastatic ability in well-differentiated pancreatic endocrine
neoplasms. Clin Cancer Res. 10:6152–6158. 2004. View Article : Google Scholar : PubMed/NCBI
|
